製品の概要
-
製品名Anti-Adenovirus Type 5 antibody
-
製品の詳細Rabbit polyclonal to Adenovirus Type 5
-
由来種Rabbit
-
アプリケーション適用あり: Neutralising, IHC-P, IHC-Fr, ELISA, WB, ICC/IFmore details
-
免疫原
Purified Adenovirus type 5
製品の特性
-
製品の状態Liquid
-
保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
-
精製度Whole antiserum
-
ポリ/モノポリクローナル
-
アイソタイプIgG
-
研究分野
関連製品
-
Compatible Secondaries
アプリケーション
Our Abpromise guarantee covers the use of ab6982 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| アプリケーション | Abreviews | 特記事項 |
|---|---|---|
| Neutralising | Use at an assay dependent concentration. This antibody will neutralize Ad5 infection in a bioassay (1/25,000 dilution for 50 % inactivation of Ad5at 1000 particles/ml). | |
| IHC-P | Use at an assay dependent concentration. PubMed: 20442708 | |
| IHC-Fr | Use at an assay dependent concentration. PubMed: 20442708 | |
| ELISA | Use at an assay dependent concentration. Recognizes Ad5 immobilized on microtiter plates. |
|
| WB | Use at an assay dependent concentration. | |
| ICC/IF | Use at an assay dependent concentration. |
ターゲット情報
-
関連性Adenoviruses are DNA viruses that cause upper respiratory tract infections, conjunctivitis, and other infections in humans. Adenoviruses were discovered in 1953. About 47 different types have been identified since then, and about half of them are believed to cause human diseases. Infants and children are most commonly affected by adenoviruses. Adenovirus infections can occur throughout the year, but seem to be most common from fall to spring. Adenoviruses are responsible for 3-5% of acute respiratory infections in children and 2% of respiratory illnesses in adults.
-
別名
- Adenovirus 5 antibody
- AdV 5 antibody
画像
-
Immunocytochemistry/ Immunofluorescence - Anti-Adenovirus Type 5 antibody (ab6982)Image courtesy of an anonymous Abreview.ab6982 staining Adenovirus type 5 in human HeLa cells by Immunocytochemistry/ Immunofluorescence. The cells were fixed in paraformaldehyde, permeabilised in 0.1% Triton and then blocked using 0.1% BSA for 16 hours at 4°C. Samples were then incubated with primary antibody at 1/800 for 1 hour at 37°C. The secondary antibody used was a donkey anti-rabbit IgG conjugated to Alexa Fluor® 546 (red) used at a 1/1000 dilution. -
Western blot - Anti-Adenovirus Type 5 antibody (ab6982)Top blot (A): ab6982 at a 1/4000 dilution staining Adenovirus type 5 capsid proteins by Western blot (ECL). Secondary = goat anti-rabbit (HRP conjuagte).
Bottom blot (B): As above, except ab6982 omitted.
Top blot (A): ab6982 at a 1/4000 dilution staining Adenovirus type 5 capsid proteins by Western blot (ECL). Secondary = goat anti-rabbit (HRP conjuagte). Bottom blot (B): As above, except ab6982 omitted. -
Other - Anti-Adenovirus Type 5 antibody (ab6982)Additional information regarding Adenovirus type 5 capsid proteins. -
Western blot - Anti-Adenovirus Type 5 antibody (ab6982)Image courtesy of an anonymous AbreviewAll lanes : Anti-Adenovirus Type 5 antibody (ab6982) at 1/10000 dilution
All lanes : human hepatocytes whole cell lysate
Lysates/proteins at 20 µg per lane.
Secondary
All lanes : HRP conjugated goat anti-rabbit secondary polyclonal antibody at 1/10000 dilution
Developed using the ECL technique.
Performed under reducing conditions.
Observed band size: 130 kDa (why is the actual band size different from the predicted?)
Exposure time: 20 secondsBlocked with 5% milk
-
Western blot - Anti-Adenovirus Type 5 antibody (ab6982)Image courtesy of an anonymous Abreview.All lanes : Anti-Adenovirus Type 5 antibody (ab6982) at 1/10000 dilution
Lane 1 : Whole cell lysate prepared from U2OS cells.
Lane 2 : Whole cell lysate prepared from U2OS cells infected with Adenovirus 5.
Lysates/proteins at 35 µg per lane.
Secondary
All lanes : Goat anti-rabbit conjugated to IRDye 700DX
Blocking step was performed using 5% milk for 1 hour at 23°C.
プロトコール
参考文献
This product has been referenced in:
- Sims JD et al. Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics. J Control Release 271:127-138 (2018). Read more (PubMed: 29288681) »
- Martin NT et al. Targeting polysialic acid-abundant cancers using oncolytic adenoviruses with fibers fused to active bacteriophage borne endosialidase. Biomaterials 158:86-94 (2018). Read more (PubMed: 29304405) »
レビューと Q&A
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"